 
			
		Three decades of progress in nasopharyngeal cancer
Tailored management for high-risk locoregional disease, together with more effective immunotherapy combinations are key areas of exploration in nasopharyngeal cancer, according to 2023 ESMO Lifetime Achievement awardee Prof. Anthony Chan
 
			 
                             
                             
                             
                             
			 
			 
                            